Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics

We extend the development of the expression of the Fisher information matrix in nonlinear mixed effects models for designs evaluation. We consider the dependence of the marginal variance of the observations with the mean parameters and assume an heteroscedastic variance error model. Complex models with interoccasions variability and parameters quantifying the influence of covariates are introduced. Two methods using a Taylor expansion of the model around the expectation of the random effects or a simulated value, using then Monte Carlo integration, are proposed and compared. Relevance of the resulting standard errors is investigated in a simulation study with NONMEM.

[1]  W. Näther.  Optimum experimental designs , 1994 .

[2]  M Davidian,et al.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.

[3]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[4]  France Mentré,et al.  Population Pharmacokinetic Analysis and Optimization of the Experimental Design for Mizolastine Solution in Children , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Michael Jackson,et al.  Optimal Design of Experiments , 1994 .

[7]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[8]  E. Walter,et al.  Robust experiment design via stochastic approximation , 1985 .

[9]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[10]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[11]  Volker C. Franke.  SAS Language and Procedures: An Introduction , 1994 .

[12]  D. Bates,et al.  Nonlinear mixed effects models for repeated measures data. , 1990, Biometrics.

[13]  D J Roe.  Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup. , 1997, Statistics in medicine.

[14]  M Davidian,et al.  Some general estimation methods for nonlinear mixed-effects models. , 1993, Journal of biopharmaceutical statistics.

[15]  Jenny Wang,et al.  A computationally efficient approach for the design of population pharmacokinetic studies , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[16]  F J Lewis,et al.  Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.

[17]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[18]  P. Laycock,et al.  Optimum Experimental Designs , 1995 .

[19]  Didier Concordet,et al.  A simulated pseudo-maximum likelihood estimator for nonlinear mixed models , 2002 .

[20]  Byron Jones,et al.  Design of cross-over trials for pharmacokinetic studies , 1999 .

[21]  T. Rothenberg.  Identification in Parametric Models , 1971 .

[22]  E. Vonesh,et al.  Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .

[23]  W K Wong,et al.  MULTIPLE-OBJECTIVE DESIGNS IN A DOSE-RESPONSE EXPERIMENT , 2000, Journal of biopharmaceutical statistics.

[24]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[25]  Michel Tod,et al.  Impact of Pharmacokinetic–Pharmacodynamic Model Linearization on the Accuracy of Population Information Matrix and Optimal Design , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[26]  France Mentré,et al.  Optimal Design of a Population Pharmacodynamic Experiment for Ivabradine , 2004, Pharmaceutical Research.

[27]  France Mentré,et al.  Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  E. Antman,et al.  Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. , 2003, British journal of clinical pharmacology.

[29]  Russell D. Wolfinger,et al.  Laplace's approximation for nonlinear mixed models. , 1993 .

[30]  L Aarons,et al.  Software for Population Pharmacokinetics and Pharmacodynamics , 1999, Clinical pharmacokinetics.

[31]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .